t
Ondine Biomedical Inc. announced on June 30, 2026, that all resolutions were duly passed at its Annual General Meeting. Shareholders re-elected Carolyn Cross and Nicolas G. Loebel with 100% of votes in favor, and Jean Charest, Jean Duvall, Junaid Bajwa, and Margaret Shaw with 83.31% of votes in favor. The appointment of auditors also passed with 99.24% of votes in favor.
| Date | 30 Jun 2026 |
| Time | 18:15:29 |
| Category | AGMs and other meetings |
| ID | 4765K |
30 June 2026
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or "the Company")
|
|
In Favor |
Against |
Withheld |
|||
Resolution |
Votes |
% |
Votes |
% |
Votes |
% |
1. Election of Directors |
|
|
|
|
|
|
Carolyn Cross |
314,158,038 |
100.00 |
0 |
0.00 |
0 |
0.00 |
Nicolas G. Loebel |
314,158,038 |
100.00 |
0 |
0.00 |
0 |
0.00 |
Jean Charest |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
Jean Duvall |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
Junaid Bajwa |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
Margaret Shaw |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
2. Appointment of Auditors |
311,758,038 |
99.24 |
0 |
0.00 |
2,400,000 |
0.76 |
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
|
|
|
Strand Hanson Limited (Nominated & Joint Financial Adviser) |
|
|
James Harris, Richard Johnson, Imogen Ellis |
+44 (0)20 7409 3494 |
|
|
|
|
Peel Hunt LLP (Broker & Joint Financial Adviser) |
|
|
James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
|
|
|
|
5654 & Company (Financial PR and IR Adviser) |
|
|
Matthew Neal, Chris Gardner, Melissa Gardiner |
+44 0791 7800 011 +44 0775 7697 357 |
Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms.
Ondine's lead product, Steriwave®, is authorized for nasal decolonisation in Canada and certain international markets. In the United States, the technology has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration and recently completed enrolment in its Phase 3 clinical trial.
The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.